More than half of non-Texans think the Lone Star State is great for business. Photo via Getty Images

As Houston and the rest of Texas continue to welcome out-of-state businesses, there’s some affirming news from a new poll. More than half of non-Texans believe the Lone Star State is a good place to launch a business.

The survey, conducted earlier this summer by Austin-based Crosswinds Media & Public Relations and Asbury Park, New Jersey-based Rasmussen Reports, a conservative-leaning polling company, found 53 percent of non-Texans had a positive perception of Texas as a place to do business. Only 23 percent of adults outside Texas had a “bad” or “very bad” view of the state’s business environment, while 24 percent said they were unsure.

The survey questioned 845 American adults who don’t live in Texas.

Thomas Graham, president and CEO of Crosswinds, says the survey results demonstrate that “the brand of the Lone Star State remains strong.”

In recent years, a number of out-of-state companies have been lured by that brand as well as the business climate in Houston. Notable examples include Hewlett Packard Enterprise, NRG Energy, and Axiom Space.

Just this year, several companies based outside Texas have revealed headquarters moves to the Houston area. Among them are:

  • Archaea Energy, which was based in Pittsburgh. The company produces renewable natural gas.
  • CDI Engineering Solutions, which was based in Philadelphia. The company provides engineering and architecture services.
  • DarkPulse, which was based in New York City. The company develops fiber-sensor technology.
  • Noodoe EV, which was based in Irvine, California. The company’s cloud-based platform manages charging stations for electric vehicles.

Jennifer Chang, CEO of Noodoe, says her company relocated its headquarters from Southern California to Texas to take advantage of Houston’s central location.

“Houston has the port and airport capacity we need to efficiently meet the unprecedented demand for EV charging stations,” Chang said in a January news release. “Houston has long been the Energy Capital of the World, mostly because of oil and gas extraction. Noodoe will help the city continue its energy legacy, only this time without fossil fuels.”

The poll from Crosswinds and Rasmussen was completed around the same time that CNBC released its ranking of the best states for doing business. Texas landed in fifth place, down one notch from its perch in CNBC’s 2021 study. A day later, CNBC put out a list of the worst states to live, with Texas appearing at No. 2 behind Arizona.

CNBC notes that skilled workers are flooding Texas, even though the quality of life here raises questions. The new arrivals “are finding limited childcare options, a stressed health care system with the highest rate of uninsured, new curbs on voting rights, and few protections against discrimination,” the cable TV network declares.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”